Minimal residual disease (MRD) testing plays a crucial role in the management of patients with cancers such as acute lymphoblastic leukemia, multiple myeloma, and acute myeloid leukemia. By detecting tiny amounts of remaining cancer cells that cannot be clinically observed, MRD testing can help clinicians assess treatment response and make important decisions about further treatment. A positive MRD test result after initial treatment suggests that some cancer cells still remain in the body and further therapy may be needed to eliminate these cells and reduce the risk of relapse. On the other hand, a negative MRD test means no detectable cancer cells are present, which indicates a very good treatment response and lower risk of the cancer coming back.

How Minimal Residual Disease Testing Works

Minimal Residual Disease Testing utilizes highly sensitive techniques like flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing to detect one cancer cell among one million normal cells. This high level of sensitivity allows detection of residual cancer that may not be visible on routine imaging scans. The tests look for specific genetic markers that are unique to a patient's cancer. These markers, typically changes in gene or chromosome structure, serve as molecular signatures to identify residual leukemia or lymphoma cells. Samples used for MRD testing include bone marrow aspirate or peripheral blood. Testing is usually performed at various timepoints during and after treatment to track response over time.

Significance of MRD Status

Numerous studies have demonstrated that MRD status measured by sensitive assays has strong predictive value and can help guide management decisions. In acute lymphoblastic leukemia, a meta-analysis found MRD-negative patients had an 89% overall survival rate at 5 years compared to only 53% for MRD-positive patients. Similarly, in multiple myeloma, being MRD-negative after initial therapy is associated with significantly longer progression-free and overall survival than being MRD-positive. The level or quantity of MRD also correlates with outcome - lower levels indicate a better prognosis. MRD status has been shown to be a more accurate predictor of relapse than other factors like age or white blood cell count. It allows high-risk patients to be identified early and treated more aggressively if needed to prevent relapse.

Get more insights on – Minimal Residual Disease Testing